Radiotherapy for Early-Stage Hodgkin's Lymphoma: A 21st Century Perspective and Review of Multiple Randomized Clinical Trials

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 5, 2008, Pages 1472-1479

  Bar Ad, Voichita ^a   Paltiel, Ora ^b   Glatstein, Eli ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Hodgkin's lymphoma; Radiotherapy

Indexed keywords

CHEMOTHERAPY; CURING; TOXICITY;

21ST CENTURIES; CURE RATES; HODGKIN'S LYMPHOMA; HODGKIN'S LYMPHOMAS; LITERATURE SEARCHES; RANDOMIZED CLINICAL TRIALS; REDUCING TREATMENTS; TREATMENT STRATEGIES;

RADIOTHERAPY;

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LAPAROTOMY; LYMPH NODE IRRADIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 56349163073     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.026     Document Type: Article

References (30)

1. Kaplan H.S. Contiguity and progression in Hodgkin's disease. Cancer Res 31 (1971) 1811-1813
2. Rosenberg S.A., and Kaplan H.S. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11 (1985) 5-22
3. Yahalom J., and Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13 Suppl. 1 (2002) 79-83
4. Glatstein E., Guernsey J.M., Rosenberg S.A., et al. The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer 24 (1969) 709-718
5. DeVita Jr. V.T., Serpick A.A., and Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 75 (1970) 881-895
6. Hoppe R.T. Radiation therapy in the management of Hodgkin's disease. Semin Oncol 17 (1990) 704-715
7. Specht L., Gray R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3888 patients. J Clin Oncol 16 (1998) 830-843
8. Rosenberg S.A. Laparotomy and splenectomy in Hodgkin's disease: A reappraisal after twenty years. Scand J Hematol 34 (1985) 289-292
9. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
10. Press O.W., LeBlanc M., Lichter A.S., et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 (2001) 4238-4244
11. Engert A., Franklin J., Eich H.T., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG7 trial. J Clin Oncol 25 (2007) 3495-3502
12. Bonadonna G., Bonfante V., Viviani S., et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22 (2004) 2835-2841
13. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organization for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24 (2006) 3128-3135
14. Ferme C., Houchingue E., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357 (2007) 1916-1927
15. Noordijk E.M., Thomas J., Fermé C., et al. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). [Abstract]. J Clin Oncol 23 Suppl. 1 (2005) 6505a
16. Diehl V., Brillant C., Engert A., et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG). [Abstract]. J Clin Oncol 23 Suppl. 1 (2005) 6506a
17. Klimm C., Engert A., Brillant C., et al. Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG. [Abstract]. J Clin Oncol 23 Suppl. 1 (2005) 6507a
18. Franklin J., Pluetschow A., Paus M., et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomized trials. Ann Oncol 17 (2006) 1749-1760
19. Longo D.L., Glatstein E., Duffey P.L., et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9 (1991) 906-917
20. Biti G.P., Cimino G., Cartoni C., et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study. J Clin Oncol 10 (1992) 378-382
21. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stage I, II, and IIIA nonbulky Hodgkin's disease. Blood 104 (2004) 3483-3489
22. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. A randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 23 (2005) 4634-4642
23. Kirby A.M., and Mikhaeel N.G. The role of FDG PET in the management of lymphoma: What is the evidence base?. Nucl Med Commun 28 (2007) 335-354
24. 18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
25. Friedberg J.W., Fischman A., Neuberg D., et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 45 (2004) 85-92
26. Hutchings M., Mikhaeel N.G., Fields P.A., et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 (2005) 1160-1168
27. 18F-FDG PET and risk-adapted therapy in Hodgkin and non-Hodgkin's lymphoma. Curr Opin Oncol 20 (2008) 206-219
28. Terasawa T., Nihashi T., Hotta T., et al. F-FDG-PET for posttherapy assessment of Hodgkin's disease and aggressive lymphoma: A systematic review. J Nucl Med 49 (2008) 13-21
29. Picardi M., De Renzo A., Pane F., et al. Randomized comparison of consolidation radiation versus observation in bulky Hodkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48 (2007) 1721-1727
30. Hutchings M., Loft A., Hansen M., et al. Clinical impact of FDG- PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78 (2007) 206-212